MR contrast media for myocardial viability, microvascular integrity and perfusion

Focal and diffuse myocardial fibrosis both contribute to regional hypoperfusion assessed by post-processing quantitative-perfusion MRI techniques

Introduction

Indications for stress-cardiovascular magnetic resonance imaging (CMR) to assess myocardial ischemia and viability are growing. First pass perfusion and late gadolinium enhancement (LGE) have limited value in balanced ischemia and diffuse fibrosis. Quantitative perfusion (QP) to assess absolute pixelwise myocardial blood flow (MBF) and extracellular volume (ECV) as a measure of diffuse fibrosis can overcome these limitations. We investigated the use of post-processing techniques for quantifying both pixelwise MBF and diffuse fibrosis in patients with clinically indicated CMR stress exams. We then assessed if focal and diffuse myocardial fibrosis and other features quantified during the CMR exam explain individual MBF findings.

Methods

This prospective observational study enrolled 125 patients undergoing a clinically indicated stress-CMR scan. In addition to the clinical report, MBF during regadenoson-stress was quantified using a post-processing QP method and T1 maps were used to calculate ECV. Factors that were associated with poor MBF were investigated.

Results

Of the 109 patients included (66 ± 11 years, 32% female), global and regional perfusion was quantified by QP analysis in both the presence and absence of visual first pass perfusion deficits. Similarly, ECV analysis identified diffuse fibrosis in myocardium beyond segments with LGE. Multivariable analysis showed both LGE (β = -0.191, p = 0.001) and ECV (β = -0.011, p < 0.001) were independent predictors of reduced MBF. In patients without clinically defined first pass perfusion deficits, the microvascular risk-factors of age and wall thickness further contributed to poor MBF (p < 0.001).

Discussion

Quantitative analysis of MBF and diffuse fibrosis detected regional tissue abnormalities not identified by traditional visual assessment. Multi-parametric quantitative analysis may refine the work-up of the etiology of myocardial ischemia in patients referred for clinical CMR stress testing in the future and provide a deeper insight into ischemic heart disease.

Rapid multislice T1 mapping of mouse myocardium: Application to quantification of manganese uptake in α-Dystrobrevin knockout mice

PURPOSE

The aim of this study was to develop a rapid, multislice cardiac T1 mapping method in mice and to apply the method to quantify manganese (Mn(2+)) uptake in a mouse model with altered Ca(2+) channel activity.

METHODS

An electrocardiography-triggered multislice saturation-recovery Look-Locker method was developed and validated both in vitro and in vivo. A two-dose study was performed to investigate the kinetics of T1 shortening, Mn(2+) relaxivity in myocardium, and the impact of Mn(2+) on cardiac function. The sensitivity of Mn(2+)-enhanced MRI in detecting subtle changes in altered Ca(2+) channel activity was evaluated in a mouse model with α-dystrobrevin knockout.

RESULTS

Validation studies showed strong agreement between the current method and an established method. High Mn(2+) dose led to significantly accelerated T1 shortening. Heart rate decreased during Mn(2+) infusion, while ejection ratio increased slightly at the end of imaging protocol. No statistical difference in cardiac function was detected between the two dose groups. Mice with α-dystrobrevin knockout showed enhanced Mn(2+) uptake in vivo. In vitro patch-clamp study showed increased Ca(2+) channel activity.

CONCLUSION

The saturation recovery method provides rapid T1 mapping in mouse hearts, which allowed sensitive detection of subtle changes in Mn(2+) uptake in α-dystrobrevin knockout mice.

MRI of the left atrium: predicting clinical outcomes in patients with atrial fibrillation

Atrial fibrillation is a significant public health burden, with clinically, epidemiologically and economically significant repercussions. In the last decade, catheter ablation has provided an improvement in morbidity and quality of life, significantly reducing long-term healthcare costs and avoiding recurrences compared with drug therapy. Despite recent progress in techniques, current catheter ablation success rates fall short of expectations. Late gadolinium-enhancement cardiovascular MRI is a well-established tool to image the myocardium and, most specifically, the left atrium. Unique imaging protocols allow for left atrial structural remodeling and fibrosis assessment, which has been demonstrated to correlate with clinical outcomes after catheter ablation, assessment of the individual's risks of thromboembolic events, and effective imaging of patients with left atrial appendage thrombus. Late gadolinium-enhancement MRI aids in the individualized treatment of atrial fibrillation, stratifying recurrence risk and guiding specific ablation strategies. Real-time MRI offers significant safety and effectiveness profiles that would optimize the invasive treatment of atrial fibrillation.

Rapid T1 mapping of mouse myocardium with saturation recovery Look-Locker method

Dynamic contrast-enhanced MRI using gadolinium or manganese provides unique characterization of myocardium and its pathology. In this study, an electrocardiography (ECG) triggered saturation recovery Look-Locker method was developed and validated for fast cardiac T(1) mapping in small animal models. By sampling the initial portion of the longitudinal magnetization recovery curve, high temporal resolution (∼ 3 min) can be achieved at a high spatial resolution (195 × 390 μm2) in mouse heart without the aid of parallel imaging or echo-planar imaging. Validation studies were performed both in vitro on a phantom and in vivo on C57BL/6 mice (n = 6). Our results showed a strong agreement between T(1) measured by saturation recovery Look-Locker and by the standard saturation recovery method in vitro or inversion recovery Look-Locker in vivo. The utility of saturation recovery Look-Locker in dynamic contrast-enhanced MRI studies was demonstrated in manganese-enhanced MRI experiments in mice. Our results suggest that saturation recovery Look-Locker can provide rapid and accurate cardiac T(1) mapping for studies using small animal models.

Preliminary assessment of cardiac short term safety and efficacy of manganese chloride for cardiovascular magnetic resonance in humans

BACKGROUND

Manganese based agents are intracellular and accumulate inside myocytes allowing for different imaging strategies compared to gadolinium contrasts. While previous agents release manganese very slowly in the circulation, MnCl2 allows for rapid Mn2+ uptake in myocytes, creating a memory effect that can be potentially explored. Data on animal models are very encouraging but the safety and efficacy of this approach in humans has not yet been investigated. Therefore, our objectives were to study the safety and efficacy of a rapid infusion of manganese chloride (MnCl2) for cardiovascular magnetic resonance (CMR) in humans.

METHODS

Fifteen healthy volunteers underwent a CMR scan on a 1.5 T scanner. Before the infusion, cardiac function was calculated and images of a short axis mid-ventricular slice were obtained using a 2D and 3D gradient-echo inversion recovery (GRE-IR) sequence, a phase-sensitive IR sequence and a single breath-hold segmented IR prepared steady-state precession acquisition for T1 calculations. MnCl2 was infused over three minutes at a total dose of 5 μMol/kg. Immediately after the infusion, and at 15 and 30 minutes later, new images were obtained and cardiac function re-evaluated.

RESULTS

There was a significant decrease in T1 values compared to baseline, sustained up to 30 minutes after the MnCl2 infusion (pre,839 ± 281 ms; 0 min, 684 ± 99; 15 min, 714 ± 168; 30 min, 706 ± 172, P = 0.003). The 2D and 3D GRE-IR sequence showed the greatest increase in signal-to-noise ratio compared to the other sequences (baseline 6.6 ± 4.2 and 9.7 ± 5.3; 0 min, 11.3 ± 4.1 and 15.0 ± 8.7; 15 min, 10.8 ± 4.0 and 16.9 ± 10.2; 30 min, 10.6 ± 5.2 and 16.5 ± 8.3, P < 0.001 for both). There was a slight increase in systolic pressure and heart rate after three and four minutes of the infusion with normalization of these parameters thereafter. Patients showed good tolerance to MnCl2 with no major adverse events, despite all reporting transient facial flush.

CONCLUSIONS

In the short term, MnCl2 appears safe for human use. It effectively decreases myocardium T1, maintaining this effect for a relatively long period of time and allowing for the development of new imaging strategies in CMR, especially in ischemia research.

Contrast agents used in cardiovascular magnetic resonance imaging: current issues and future directions

Cardiovascular MRI is being increasingly used in the evaluation of ischemic heart disease, cardiac masses, complex congenital heart disease, and morphologic evaluation of the vascular anatomy throughout the body. Many and varied contrast media may be used to increase the sensitivity and specificity of detecting and evaluating various pathologies, and a knowledge of the different mechanisms of action, distributions and safety profiles of these agents is required for safe and effective imaging. This article reviews the currently available magnetic resonance (MR) contrast media, discusses the risks and benefits, and gives illustrated examples of current clinical applications in cardiovascular disease. A literature search covered the period 1990 to the present with the use of multiple databases including MEDLINE, PUBMED, SciSearch and Google Medical. All identified studies containing information relevant to the topic of cardiovascular MRI and cardiovascular MR contrast agents and their uses and properties were evaluated. Evaluation was limited to studies in English. The conclusions were that the use of contrast agents vastly increases the diagnostic yield, sensitivity and specificity of cardiovascular MRI in the non-invasive diagnosis of the full breadth of cardiovascular pathology. The use of contrast MRI for investigating ischemic heart disease, cardiac masses, and congenital heart disease and in angiography is now well established, and the referring physician, cardiologist, or radiologist requires an in-depth knowledge of the safety profiles and correct dosing of commonly prescribed contrast agents. As the number of MR contrast agents on the market continues to increase, knowledge of the basic mechanism of action is vital for keeping abreast of how new and emerging agents will affect clinical practice in the future.

MR Guidance of Targeted Injections into Border and Core of Scarred Myocardium in Pigs

PURPOSE

To use (a) dysprosium-based contrast agent (sprodiamide) to confirm the site of myocardial injection and (b) T1-enhancing magnetic resonance (MR) contrast media to mark the myocardial target and T2*-enhancing contrast media to demonstrate injection sites in the margins or core of infarction on delayed contrast-enhanced images.

MATERIALS AND METHODS

Approval of the institutional committee on animal research was obtained. A phantom and six pigs subjected to chronic infarction (8 weeks) underwent MR-guided experiments. At inversion-recovery gradient-echo imaging, gadoterate meglumine (0.1 mmol/kg) was intravenously administered to delineate scar tissue. A catheter fitted with multiple receiver coils was used to visualize catheter navigation and injection sites. A steady-state free precession (balanced fast field-echo) sequence was used for MR fluoroscopy. A high-resolution multiphase balanced gradient-echo cine MR sequence was used after intramyocardial deposition of sprodiamide. The border and core of scarred myocardium were characterized histopathologically. The 95% confidence interval (CI) was used to demonstrate the range, extent of hyperenhanced and hypoenhanced regions after contrast media administration.

RESULTS

In the phantom and in vivo, the actively guided catheter produced a high signal intensity at the terminal portion of the shaft and tip. Scarred myocardium was recognized as a bright region on gadoterate meglumine-enhanced images. Intramyocardial injection of sprodiamide caused local and persistent signal intensity loss, and the extent was volume dependent on balanced fast field-echo and T2-weighted turbo spin-echo images. At 5 minutes after administration of 0.2, 0.4, and 0.6 mL of sprodiamide, the 95% CIs of the extents of the hypoenhanced regions were 0.08%, 0.23%; 0.27%, 0.51%; and 0.46%, 0.70%, respectively, of left ventricular (LV) surface area (P < .05, paired t test). Failure of intramyocardial injection was confirmed by a brief signal loss of LV chamber blood.

CONCLUSION

Sprodiamide allows visualization of injection sites within enhanced infarction. A catheter with integrated receiver coils aided in effective catheter guidance and precise intramyocardial injection.

Contrast agents and cardiac MR imaging of myocardial ischemia: from bench to bedside

This review paper presents, in the first part, the different classes of contrast media that are already used or are in development for cardiac magnetic resonance imaging. A classification of the different types of contrast media is proposed based on the distribution of the compounds in the body, their type of relaxivity and their potential affinity to particular molecules. In the second part, the different uses of the extracellular type of T1-enhancing contrast agent for myocardial imaging is covered from the detection of stable coronary artery disease to the detection and characterization of chronic infarction. A particular emphasis is placed on the clinical use of gadolinium-chelates, which are the universally used type of MRI contrast agent in the clinical routine. Both approaches, first-pass magnetic resonance imaging (FP-MRI) as well as delayed-enhanced magnetic resonance imaging (DE-MRI), are covered in the different situations of acute and chronic myocardial infarction.

Magnetic resonance approaches and recent advances in myocardial perfusion imaging

Myocardial perfusion imaging identifies the presence of coronary artery stenoses and defines the functional significance of those lesions. Single photon emission computed tomography and positron emission tomography have established roles. Cardiac magnetic resonance is evolving as a promising new modality in the evaluation of myocardial perfusion. This article summarizes the current capability and recent advancements in magnetic resonance perfusion imaging.

The influence of myocardial blood flow and volume of distribution on late Gd-DTPA kinetics in ischemic heart failure

PURPOSE

To determine the mechanism of enhancement of contrast-enhanced MRI (ceMRI) in chronic ischemic myocardium. While ceMRI can identify scar tissue in chronic ischemic myocardium, the mechanism of enhancement is not completely understood.

MATERIALS AND METHODS

A total of 11 patients with ischemic heart failure (ejection fraction [EF] 28 +/- 9%) were imaged with ceMRI and positron emission tomography (PET) to measure myocardial blood flow (MBF). Longitudinal relaxation rate (T1) of blood, normal tissue, and scar tissue defined by ceMRI was determined before and two to 50 minutes after contrast (Look Locker technique), and the partition coefficient (lambda) and volume of distribution (VD) were calculated.

RESULTS

In scar and viable tissue, T1 was significantly different over the whole period after contrast, but not before contrast. However, T1 of scar and blood were similar five to 15 minutes post contrast, making the detection of subendocardial defects difficult. lambda reached an initial steady state in viable tissue, but was delayed (20 minutes) in scar tissue. VD in scar was double that of viable tissue (0.54 +/- 0.01 vs. 0.29 +/- 0.02, respectively) indicating an increased interstitial space. Contrast wash-in kinetics correlated moderately with MBF (r = -0.36), but well with the combination of MBF and VD (r = 0.59).

CONCLUSION

Late myocardial contrast kinetics depend on both MBF and VD; however the increased VD seems to be the main mechanism for the late enhancement effect.

MRI in guiding and assessing intramyocardial therapy

Cardiovascular intervention, using MRI guidance, is challenging for clinical applications. Real-time imaging sequences with high spatial resolution are needed for monitoring intramyocardial delivery of drug, gene, or stem cell therapies. New generation MR scanners make local intramyocardial and vascular wall therapies feasible. Contrast-enhanced MRI is used for assessing myocardial ischemia, infarction, and scar tissue. Active (microcoils) and passive (T1 and T2* mechanisms) tracking methods have been used for visualization of endovascular catheters. Safety issues related to potential heating of endovascular devices is still a major obstacle for MRI-guided interventions. Fabrication of MRI-compatible interventional devices is limited. Noninvasive imaging strategies will be critical in defining spatial and temporal characteristics of angiogenesis and myocardial repair as well as in assessing the efficacy of new therapies in ischemic heart disease. MRI contrast media improve the capability of MRI by delineating the target and vascular tree. Labeling stem cells enables MRI to trace distribution, differentiation, and survival in myocardium and vascular wall. In the long term, MRI in guiding and assessing intramyocardial therapy may circumvent the limitations of peripherally administered cell therapy, X-ray angiography, and nuclear imaging. MRI represents a highly attractive discipline whose systematic development will foster the implementation of new cardiac and vascular therapies.

MR imaging of apparent small-bowel perfusion for diagnosing mesenteric ischemia: feasibility study

The purpose of this study, which was approved by the institutional review board, was to assess the differentiation of individuals with from those without mesenteric ischemia. All subjects provided written informed consent. Six healthy volunteers and six patients with documented chronic mesenteric ischemia underwent magnetic resonance (MR) imaging with and without oral caloric stimulation. After intravenous administration of paramagnetic contrast material, signal intensity values of the small-bowel wall were measured up to 130 seconds after contrast material injection. Volunteers and patients, respectively, had maximum enhancement of the bowel wall between 70 and 85 seconds after contrast material administration that amounted to 269% and 267% without and 425% and 333% with caloric stimulation. MR imaging assessment of small-bowel perfusion is possible and seems feasible for differentiating individuals with from those without mesenteric ischemia.

Contrast-enhanced MR imaging of the heart: overview of the literature

The use of magnetic resonance (MR) imaging for cardiac diagnosis is expanding, aided by the administration of paramagnetic contrast agents for a growing number of clinical applications. This overview of the literature considers the principles and applications of cardiac MR imaging with an emphasis on the use of contrast media. Clinical applications of contrast material-enhanced MR imaging include the detection and characterization of intracardiac masses, thrombi, myocarditis, and sarcoidosis. Suspected myocardial ischemia and infarction, respectively, are diagnosed by using dynamic first-pass and delayed contrast enhancement. Promising new developments include blood pool contrast media, labeling of myocardial precursor cells, and contrast-enhanced imaging at very high fields.

Assessment of myocardial ischemia and viability using cardiac magnetic resonance

Cardiac magnetic resonance (CMR) is a burgeoning area of noninvasive cardiac imaging. Today, its clinical utility spans from the qualitative and quantitative assessment of cardiac function and morphology to the challenging task of determining the severity and reversibility of coronary heart disease. Advances in magnet and coil design, pulse sequence, and contrast media have contributed greatly, helping CMR become the multipurpose tool of today's cardiac imaging. This article reviews and explores some of the most exciting clinical applications of CMR in the assessment of coronary artery disease.

Imaging of myocardial infarction: comparison of magnevist and gadophrin-3 in rabbits

OBJECTIVES

This study was designed to determine the enhancement profile of a necrosis-specific contrast agent (gadophrin III) in comparison to a standard extracellular agent on T1-weighted magnetic resonance (MR) images in acute and chronic myocardial infarctions (MIs).

BACKGROUND

Contrast-enhanced MR imaging demonstrated the ability to accurately quantify infarct size; however, some controversies persist about which contrast medium is best suited.

METHODS

Fifteen rabbits underwent thoracotomy and permanent occlusion of a branch of the left coronary artery. Two animals died before imaging, eight were examined 48 h after occlusion and five animals were imaged six weeks following induction of infarction. All animals received 50 micromol/kg of gadophrin-3 24 h before the MR examination. Continuous short-axis views were collected using an inversion recovery turbo fast low angle shot sequence. Imaging was repeated 5 to 10 min following additional injection of 100 micromol/kg of Magnevist. The area of hyperenhancement demarcated following gadophrin-3 injection was compared with the region of hyperenhancement seen on gadophrin-3 plus Magnevist enhanced image using triphenyltetrazolium chloride (TTC) staining as the standard of reference.

RESULTS

In acute MI the mean difference in size of hyperenhancement seen on the two different in vivo MR scans was -1.8 +/- 6.0 mm(2) (p > 0.05). Both measurements showed excellent agreement with TTC staining. Chronic MIs showed no enhancement with gadophrin-3, whereas application of Magnevist resulted in hyperenhancement. CONCLUSIONS; Standard extracellular contrast agents do not overestimate the size of acute MI. The combination of gadophrin-3 and Magnevist can distinguish acute and chronic myocardial injury because chronic MIs do not enhance with gadophrin-3.

Factor analysis of medical image sequences improves evaluation of first-pass MR imaging acquisitions for myocardial perfusion

RATIONALE AND OBJECTIVES

Factor analysis of medical image sequences (FAMIS) applied to gadolinium chelate-enhanced subsecond magnetic resonance (MR) imaging was evaluated as a postprocessing method for assessing myocardial perfusion in coronary artery disease (CAD).

MATERIALS AND METHODS

To assess the accuracy of motion correction, five normal volunteers underwent MR imaging at rest. Thirteen patients with well-documented CAD and no myocardial infarction underwent MR imaging at rest and after dipyridamole administration. After motion correction, a single myocardial tissue factor (FAMISt) image was obtained with FAMIS for each raw MR imaging series acquisition. To evaluate how FAMIS could improve the analysis of these acquisitions, five readers visually assessed myocardial perfusion with FAMISt and raw MR images, and a multicase, multireader receiver operating characteristic analysis was performed.

RESULTS

FAMISt images significantly improved detection of the perfusion defects when compared with raw MR images (P = .002). Areas under the receiver operating characteristic curves ranged from 0.84 to 0.93 with FAMISt images and from 0.48 to 0.85 with raw MR images.

CONCLUSION

FAMIS applied to first-pass MR imaging series provided myocardial perfusion images that improve the objective assessment of myocardial perfusion in patients with CAD.

Magnetic resonance imaging in coronary heart disease

Modern level of cardiac magnetic resonance imaging (MRI) development already allows its routine use (with proper indications) in coronary heart disease patients for studies of heart morphology and functions, performance of stress tests for evaluation of myocardial perfusion and contractile function. Coronary MRA and some other new MR techniques are close to its wide-scale clinical application. It has been shown that cardiac MRI is a valuable tool for detection of postinfarction scars, aneurysms, pseudoaneurysms, septal defects, mural thrombi and valvular regurgitations. Due to intrinsic advantages of the method it is of special value when these pathological conditions cannot be fully confirmed or excluded with echocardiography. MRI is recognized as the best imaging method for quantification of myocardial thickness, myocardial mass, systolic myocardial thickening, chamber volumes, ejection fraction and other parameters of global and regional systolic and diastolic function. MRI is used in studies of cardiac remodeling in postinfarction patients. The most attractive areas for cardiovascular applications of MRI are assessment of myocardial perfusion and non-invasive coronary angiography. Substantial progress has been achieved in these directions. There are some other new developments in studies of coronary artery disease with MRI. High-resolution MR is used for imaging and quantification of atherosclerotic plaque composition in vivo. Intravascular MR devices suitable for performing imaging-guided balloon angioplasty are created. But before MRI will be widely accepted by the medical community as a important cardiovascular imaging modality several important problems have to be solved. Further technical advances are necessary for clinical implementation of all major diagnostic capabilities of cardiac MRI. The subjective obstacles for growth of clinical applications of cardiac MRI are lack of understanding of its possibilities and benefits both by clinicians and radiologists themselves. So proper training of specialists and promotion of this promising modality among the medical community are necessary.